Posted by Michael Wonder on 11 Jul 2023
ICER developing special report for submission to CMS as part of public comment process on Medicare drug price negotiations
11 July 2023 - ICER to assess apixaban and rivaroxaban, two drugs that seem likely to be among those in the first cycle of drug price negotiation.
The ICER announced today that it is developing a special report evaluating the evidence on apixaban (Eliquis, Bristol-Myers Squibb) and rivaroxaban (Xarelto, Bayer) for the treatment of non-valvular atrial fibrillation.
